PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20860416-3 2010 Therapy with candesartan cilexetil 0.05, 0.20, and 0.40 mg/kg/day for 4 weeks was effective in the treatment of hypertension in children aged 1 to <6 years, inducing significant dose-dependent reductions from baseline in sitting SBP (SSBP) [primary endpoint] and sitting DBP (SDBP) in the double-blind phase of a randomized, parallel-group, multinational, dose-ranging clinical study. candesartan 13-24 selenium binding protein 1 Homo sapiens 232-235 22406464-5 2012 When we divided participants by their time of candesartan administration, the relationship between the decrease in log-transformed BNP and asleep SBP was still significant in both the awakening-dosing group (beta = 0.21, P = 0.028) and the bedtime-dosing group (beta = 0.21, P = 0.029). candesartan 46-57 selenium binding protein 1 Homo sapiens 146-149 21602709-10 2011 Candesartan reduced combined macrovascular and microvascular complication risk; the age and baseline SBP overall adjusted hazard ratio for candesartan vs. placebo was 0.85 [95% confidence interval (CI) 0.72-0.99], P = 0.040, reflecting hazard ratios of 0.86 (0.66-1.13) for baseline normotensive individuals and 0.83 (0.68-1.02) for hypertensive patients. candesartan 139-150 selenium binding protein 1 Homo sapiens 101-104 20016523-3 2010 The objective of this analysis was to compare the efficacy of candesartan and losartan with respect to reduction in systolic and diastolic BP (SBP and DBP). candesartan 62-73 selenium binding protein 1 Homo sapiens 143-146 12946547-11 2003 When we interrupted perindopril and candesartan therapy for a 1-month washout period, changes in SBP and DBP values were significant compared with month 12 in both groups (all P < 0.05). candesartan 36-47 selenium binding protein 1 Homo sapiens 97-100 19090875-3 2008 Systolic (SBP)/diastolic (DBP) blood pressure declined 8.6/4.8-11.2/8.0 mm Hg with candesartan and 3.7/1.8 mm Hg with placebo (P<.01 compared to placebo for SBP and for the mid and high doses for DBP; placebo-corrected 4.9/3.0-7.5/6.2 mm Hg). candesartan 83-94 selenium binding protein 1 Homo sapiens 10-13 12946547-9 2003 Significant changes from baseline to month 12 occurred with candesartan in SBP and DBP (both P < 0.01) and AER (P < 0.05). candesartan 60-71 selenium binding protein 1 Homo sapiens 75-78 33170247-13 2020 Candesartan reduced SBP by -6.56 mm Hg (P < .001; n = 240). candesartan 0-11 selenium binding protein 1 Homo sapiens 20-23 12410853-14 2002 CONCLUSIONS: Candesartan cilexetil significantly reduced SBP and DBP and increased control (61.2%) of BP in hypertensive menopausal women. candesartan 13-24 selenium binding protein 1 Homo sapiens 57-60 11929332-5 2002 Treatment for 8 weeks with candesartan cilexetil 16 mg/hydrochlorothiazide 12.5 mg or candesartan cilexetil 16 mg induced SBP/DBP reductions of 12.0/7.5 mm Hg and 7.5/5.5mm Hg, respectively (p < 0.05 both comparisons). candesartan 27-38 selenium binding protein 1 Homo sapiens 122-125